Industry veteran David Zaccardelli has been appointed as President and CEO of Verona Pharma.
Dr Zaccardelli, who also joins the company’s board, replaces CEO Jan-Anders Karlsson ho is retiring after eight years to pursue non-executive roles.
Dr Zaccardelli most recently served as President and CEO of Dova Pharmaceuticals until it was acquired by Sobi in October last year.
Previously, he held several senior management roles including Chief Operating Officer at United Therapeutics Corporation.
In addition, Mark W. Hahn, a seasoned pharmaceutical finance executive, will join Verona Pharma as Chief Financial Officer with effect from March 1, 2020.
Mr. Hahn previously served as the CFO of Dova Pharmaceuticals and Cempra and raised over $600 million to support product development and commercialization activities of those companies.
Piers Morgan will continue to serve as CFO of Verona Pharma through February 28, 2020 to provide an efficient transition and complete required financial reporting.
Both Dr Zaccardelli and Mr Hahn will be based in North Carolina in the US, where the majority of the Company’s clinical team are located, to lead the development and commercialization of ensifentrine for respiratory diseases including chronic obstructive pulmonary disease, asthma and cystic fibrosis.